Loading...
Loading...
CVAC| Name | Value |
|---|---|
| Revenues | 11.7M |
| Cost of Revenue | 80.0M |
| Gross Profit | -68.3M |
| Operating Expense | 53.7M |
| Operating I/L | -121.5M |
| Other Income/Expense | -7.2M |
| Interest Income | -6.6M |
| Pretax | -128.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -128.8M |
CureVac N.V. is a clinical-stage biopharmaceutical company specializing in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company's primary focus is on developing prophylactic vaccines, including mRNA-based vaccine candidates for SARS-CoV-2, rabies virus glycoprotein, influenza, lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. Additionally, CureVac N.V. is involved in the development of RNA-based cancer immunotherapies for treating cutaneous melanoma, adenoidcystic carcinoma, and squamous cell cancer of the skin, head, and neck.
